GSK Share PerformanceMore
|52 week high||1,745.5 11/10/16|
|52 week low||1,363.0 24/06/16|
|52 week change||197.0 (13.70%)|
|4 week volume||202,070,027 27/04/17|
Latest News« previous» nextMore
22/05/2017 - 16:45 RNS
RNS Number: 8838F GlaxoSmithKline PLC 22 May 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr P C Thomson b) Position/status President, Global Affairs c) Initial notification/ amendment Initial notification 2. Details of the issuer, emission allowance market participan...
22/05/2017 - 16:40 RNS
RNS Number: 8831F GlaxoSmithKline PLC 22 May 2017 GlaxoSmithKline plc (the ' Company ') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Mr R G Connor b) Position/status President, Global Manufacturing & Supply c) Initial notification/ amendment Initial Notification 2. Details of the issuer, emission allowance m...
22/05/2017 - 14:28 StockMarketWire
GlaxoSmithKline has presented data from a post-hoc analysis of the phase IIIb MUSCA study in which first-in-class biolog...
22/05/2017 - 14:23 RNS
RNS Number: 8589F GlaxoSmithKline PLC 22 May 2017 Issued: Monday 22 May, 2017, London UK - LSE Announcement GSK presents data at ATS on treatment effect of Nucala (mepolizumab) in severe asthma according to blood eosinophil level GlaxoSmithKline plc (LSE/NYSE:GSK) today presented data from a post-hoc analysis of the phase IIIb MUSCA study in...
22/05/2017 - 10:16 Money Observer
Heather Connon takes the 2017 Dogs for their first airing of the year and finds that between them they're setting a crackin...
19/05/2017 - 13:57 Interactive Investor
This share is in freefall after delays to the approval process for one of its drugs. However, David Brenchley finds that anal...
18/05/2017 - 13:26 Interactive Investor
If you're looking for capital growth, don't bother with big pharma, argues fund manager Paul Mumford. He tells Lee Wild...
18/05/2017 - 07:00 RNS
RNS Number: 4838F GlaxoSmithKline PLC 17 May 2017 Issued: 17 th May 2017, London, UK - LSE Announcement GSK announces NEJM publication of positive phase III study investigating mepolizumab in patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA) D ouble-blind, placebo-controlled study of mepolizumab in patients with EGPA demonstra...
|Dividend yield||4.893 %|
Latest discussion posts More
“Over a holding period of more than fifteen years, I have consistently believed that GlaxoSmithKline was capable of delivering growth and realising shareholder value. Neither ...”▼
“""Maybe this time next year he'll be buying back GSK for his very latest ultra-new income super fund."" Grill let's hope not, I'm not sure GSK management want anymore of his ...”▼
Codes & Symbols
|Symbols||GSK, LSE:GSK, GSK.L, GSK:LN, LON:GSK, XLON:GSK|